NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Emergent BioSolutions, Inc. (NYSE: EBS) on behalf of Emergent stockholders. Our investigation concerns whether Emergent has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On March 31, 2021, the New York Times published an article reporting on the accidental contamination at an Emergent manufacturing plant in Baltimore of coronavirus vaccines developed by Johnson & Johnson and AstraZeneca PLC. According to reporting by the Associated Press, the Emergent factory where the contamination occurred had a series of lapses observed by the U.S. Food and Drug Administration in April 2020.
On this news, Emergent’s stock price fell $12.45 per share, or 13.4%, to close at $80.46 per share on April 1, 2021.
If you purchased or otherwise acquired Emergent shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at firstname.lastname@example.org, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.